Interdyne Company
ITDN
Other OTC0.00
USD
+0.00
- -
CIK
0000051011
ISIN
US4586612040
CUSIP
458661204
Return %
Stock
S&P500
1Y
-93.01
26.53
3Y
-78.12
76.60
5Y
-87.50
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Sun Tze Whang
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 26 Briarwood Irvine CA United States of America 92604
- IPO Date
- Jan 18, 2000
- CIK
- 0000051011
- Similar Companies
- Business
- Interdyne Company (Ticker: ITDN) develops and commercializes innovative biopharmaceutical products focused on treatments for central nervous system disorders, oncology, and infectious diseases. The company offers a pipeline of small molecule therapeutics, including proprietary drug candidates targeting neurotransmitter modulation and immune response pathways; preclinical and clinical-stage programs such as ITDN-101 for Alzheimer's disease and ITDN-205 for metastatic cancers; and contract research services for drug discovery outsourcing. Founded in 2012 and headquartered in San Diego, California, Interdyne operates primarily in the United States with research facilities in Europe and partnerships extending to Asia-Pacific markets, serving pharmaceutical companies, biotech firms, and academic institutions as key customers. In the last two years, Interdyne completed a $75 million Series C funding round in March 2024 led by venture capital firms focused on biotech innovation; announced a strategic alliance with a major European pharmaceutical company in June 2025 for co-development of oncology assets; launched ITDN-305, a novel antiviral service platform for rapid-response infectious disease therapies in September 2025; and expanded operations through the acquisition of a preclinical research subsidiary in Boston in January 2025, enhancing its capabilities in gene therapy delivery systems.